NLZ0 Stock Overview
A commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NeuroMetrix, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.94 |
| 52 Week High | US$12.75 |
| 52 Week Low | US$0.94 |
| Beta | 2.23 |
| 1 Month Change | 0% |
| 3 Month Change | -18.28% |
| 1 Year Change | -91.35% |
| 3 Year Change | -96.42% |
| 5 Year Change | -98.62% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NLZ0 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -0.4% |
| 1Y | -91.4% | -3.6% | 4.2% |
Return vs Industry: NLZ0 underperformed the German Medical Equipment industry which returned 3.7% over the past year.
Return vs Market: NLZ0 underperformed the German Market which returned -1.2% over the past year.
Price Volatility
| NLZ0 volatility | |
|---|---|
| NLZ0 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: NLZ0's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine NLZ0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 27 | Shai Gozani | www.neurometrix.com |
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.
NeuroMetrix, Inc. Fundamentals Summary
| NLZ0 fundamental statistics | |
|---|---|
| Market cap | €3.40m |
| Earnings (TTM) | -€5.17m |
| Revenue (TTM) | €5.97m |
0.6x
P/S Ratio-0.7x
P/E RatioIs NLZ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NLZ0 income statement (TTM) | |
|---|---|
| Revenue | US$6.43m |
| Cost of Revenue | US$2.10m |
| Gross Profit | US$4.33m |
| Other Expenses | US$9.90m |
| Earnings | -US$5.57m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 22, 2024
| Earnings per share (EPS) | -5.19 |
| Gross Margin | 67.32% |
| Net Profit Margin | -86.64% |
| Debt/Equity Ratio | 0% |
How did NLZ0 perform over the long term?
See historical performance and comparison